Analyzing Takeda Pharmaceutical (TAK) & Its Rivals

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Takeda Pharmaceutical to similar companies based on the strength of its institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current ratings for Takeda Pharmaceutical and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical 0 1 2 1 3.00
Takeda Pharmaceutical Competitors 7870 13816 25857 1043 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 30.33%. Given Takeda Pharmaceutical’s competitors higher probable upside, analysts plainly believe Takeda Pharmaceutical has less favorable growth aspects than its competitors.

Risk and Volatility

Takeda Pharmaceutical has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical’s competitors have a beta of -0.05, indicating that their average stock price is 105% less volatile than the S&P 500.

Earnings & Valuation

This table compares Takeda Pharmaceutical and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Takeda Pharmaceutical $28.32 billion -$1.01 billion 28.63
Takeda Pharmaceutical Competitors $3.56 billion $3.19 billion 559.27

Takeda Pharmaceutical has higher revenue, but lower earnings than its competitors. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.2%. Takeda Pharmaceutical pays out 63.2% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.4% and pay out 48.0% of their earnings in the form of a dividend. Takeda Pharmaceutical lags its competitors as a dividend stock, given its lower dividend yield and higher payout ratio.

Profitability

This table compares Takeda Pharmaceutical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical 8.26% 11.51% 5.59%
Takeda Pharmaceutical Competitors -2,391.71% -206.07% -14.88%

Summary

Takeda Pharmaceutical competitors beat Takeda Pharmaceutical on 8 of the 15 factors compared.

Takeda Pharmaceutical Company Profile

(Get Free Report)

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.